SYT7 and neuromuscular disease caused by qualitative or quantitative defects of dysferlin: Recently, halofuginone have been shown to directly affect myoblast fusion in the mouse models for DMD and dysferlinopathy [19,25] and improve membrane repair in dysferlinopathy, probably via synaptotagmin-7 compensation [31].